Literature DB >> 21516065

Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation.

Jason M Ali1, Luca Bonomo, Rebecca Brais, William J H Griffiths, David J Lomas, Emmanuel L Huguet, Raaj K Praseedom, Neville V Jamieson, Asif Jah.   

Abstract

BACKGROUND: Liver transplantation in the presence of cholangiocarcinoma (CCA) generally carries a poor prognosis. However, the outcome of patients found to have incidental CCA (iCCA) on explanted liver histology is less clear. We have evaluated the outcomes of iCCA in our liver transplant population.
METHODS: A retrospective search was made of the transplantation and histopathology databases for patients fulfilling our definition for iCCA. All records, including archived histopathologic slides were retrieved and analyzed.
RESULTS: Of 1288 patients undergoing liver transplantation over the 20-year period 1988-2008, nine were found to have iCCA (0.70%). Seven of the nine patients underwent liver transplantation for primary sclerosing cholangitis. Three additional patients who were transplanted for presumed hepatocellular carcinoma that subsequently turned out to be CCA were identified, but excluded from survival analysis. The majority of tumors were early stage (T2 or below), but five (55.6%) had positive biliary transection margins. Median follow-up was 51 months. Five patients (55.6%) developed recurrence of CCA after a median interval of 25.8 months, giving a disease-free survival of 100% at 1 year and 66.7% at 3 years. Three patients have died of recurrence, with a median interval from transplantation of 25 months. The overall 3-year survival was 66.7%.
CONCLUSIONS: Patients found to have iCCA after liver transplantation have a relatively poor prognosis. Prospective liver transplant recipients, especially those with primary sclerosing cholangitis, should be investigated rigorously to exclude CCA.

Entities:  

Mesh:

Year:  2011        PMID: 21516065     DOI: 10.1097/TP.0b013e31821aba57

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

2.  Hilar cholangiocarcinoma: no longer hopeless.

Authors:  Charles B Rosen
Journal:  Dig Dis Sci       Date:  2014-05       Impact factor: 3.199

Review 3.  Overview of the indications and contraindications for liver transplantation.

Authors:  Stefan Farkas; Christina Hackl; Hans Jürgen Schlitt
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

4.  Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN) 2021 Abstracts.

Authors: 
Journal:  Can Liver J       Date:  2021-04-29

Review 5.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

6.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

7.  Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

Authors:  James H Tabibian; Christy E Trussoni; Steven P O'Hara; Patrick L Splinter; Julie K Heimbach; Nicholas F LaRusso
Journal:  Lab Invest       Date:  2014-07-21       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.